Augmenix, Inc.

Medical DevicesMassachusetts, United States51-200 Employees

Augmenix, Inc. is a privately held medical device company based in Bedford, Massachusetts, that develops and commercializes products built on its hydrogel technology for use in radiation oncology and urology. Its SpaceOAR System uses an absorbable hydrogel to create a temporary separation between the rectum and the prostate during radiation therapy, reducing rectal radiation exposure and the risk of long-term injury; it is FDA-cleared and described as the first and only device of its kind for this purpose. The company has also developed TraceIT Tissue Marker, an absorbable marker visible on multiple imaging modalities to aid in marking soft tissue for surgical procedures; this technology is licensed from Incept, LLC. Together, these offerings reflect Augmenix’s approach of applying hydrogel-based solutions to improve precision and safety in cancer treatment and subsequent surgeries.

Based in the medical equipment manufacturing sector, Augmenix targets clinicians and their patients undergoing prostate cancer radiotherapy and related surgical planning. The SpaceOAR product helps clinicians reduce unintended radiation damage to normal organs, while TraceIT supports accurate tissue localization. The company has engaged in partnerships with patient groups, such as Us TOO, to support education and empowerment of patients and their families.

Sign up for free to view info

Email Format Employee directory